Huapont Life Sciences Co (002004) Fair Value & Analysis
Basic Materials · CN · Market cap 8.6B CNY
Analysis
Huapont Life Sciences Co (002004) currently trades at ¥4.15, while our model-based Fair Value estimate is ¥7.55 — implying the stock looks roughly 81.9% undervalued today. We read business quality at 80/100 (high quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and raw materials. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management products. In addition, the company provides pesticide technical, intermediate and preparation products, and GLP registration technical services. Further, it engages in the research and development, production, and sales of fine chemical products and polymer materials, as well as provides tourism services and agent for the promotion of preparation products. The company was formerly known as Huapont-Nutrichem Co., Ltd. and changed its name to Huapont Life Sciences Co.,Ltd. in September 2015. Huapont Life Sciences Co.,Ltd. was founded in 1992 and is headquartered in Chongqing, China.
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.